MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer
Guoou Xie, Tiezheng Qi, Yiyan Yao, Dongcai Feng, Weimin Zhou · 2024
Read MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer by Guoou Xie, Tiezheng Qi, Yiyan Yao, Dongcai Feng, Weimin Zhou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11532506.txt.
Description
Guoou Xie, Tiezheng Qi, Yiyan Yao, Dongcai Feng, and Weimin Zhou report a 2024 study on a gene that may sort bladder cancer patients by likely course and best care. Bladder cancer is the tenth most common cancer round the world, and its mixed nature blunts current tests and drugs. The tissue around a tumour shapes its growth, so genes that track that setting could guide care.
The team focused on one such gene and first read its immune profile across cancers. In bladder cancer alone, high gene levels linked to a friendly set of traits: better outlook, a calmer subtype, and low immune cell entry. Low levels linked to poor outlook, a harsher subtype, and high immune entry, but also to more gain from radiation and immune drugs. The gene may help split patients for the right treatment.
Catalog record
| CREATOR | Guoou Xie, Tiezheng Qi, Yiyan Yao, Dongcai Feng, Weimin Zhou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |